Antimicrobial tubular catheter

By functionalizing antimicrobial peptides, especially RiLK1 peptides, the problem of insufficient protection ability for microorganisms and pathogens in the prior art is solved, effective protection against a variety of microorganisms and viruses is achieved, and costs are reduced.

CN115666237BActive Publication Date: 2024-12-06SANIDRINK SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180038103.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-27
Filing Date
2021-03-26
Publication Date
2024-12-06
Estimated Expiration
2041-03-26

AI Technical Summary

Technical Problem

Existing tubular catheters are difficult to effectively prevent microbial and pathogen contamination in the food and medical fields, especially the lack of protection against Gram-negative and positive bacteria, fungi and yeasts, and the synthesis and purification costs of antibacterial agents are high.

Method used

Using tubular catheters functionalized by specific antimicrobial peptides such as RiLK1 peptides, the antimicrobial peptides are attached to the surface of the tubular catheter by covalent attachment or coating, providing broad-spectrum antimicrobial activity and preventing viral contamination.

Benefits of technology

Effective protection against Gram-negative and positive bacteria, fungi, yeast and viruses is achieved, reducing the risk of contamination of tubular catheters, and reducing the cost of synthesis and purification of antibacterial agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003964525770000201
    Figure BDA0003964525770000201
  • Figure BDA0003964525770000211
    Figure BDA0003964525770000211
  • Figure BDA0003964525770000231
    Figure BDA0003964525770000231
Patent Text Reader

Abstract

This invention relates to tubular conduits preferably made of biodegradable polymeric materials, the outer and / or inner surfaces of which are functionalized with an antimicrobial peptide having the sequence (I) or its salt or solvate: X1LX2WVX3IWX4X 5( I), wherein X1, X2, X3, X4, and X5 are independently selected from K and R, and wherein each amino acid is independently in the D or L configuration. The purpose of functionalizing the tubular catheter of the present invention with at least one antimicrobial peptide is to address contamination problems caused by Gram-negative bacteria, Gram-positive bacteria, fungi, yeasts, and / or viruses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a tubular conduit, such as a drinking straw, the outer and / or inner surface of which is functionalized with an antimicrobial peptide. Background Art

[0002] The rapid increase in highly resistant pathogens is a global challenge facing the food and beverage industry as well as the healthcare industry.

[0003] In particular, drinking water has been considered one of the main requirements for the health and sustainability of human life.

[0004] However, the World Health Organization (WHO) reports that 884 million people lack access to drinking water and that 2.2 million deaths (mostly among children) are attributable to diarrhoea, which is spread through contaminated water and / or poor sanitation or hygiene.

[0005] Bottled water is often recommended for hospitalized patients with compromised immune systems. The American Society for Microbiology reports that bacteria can also grow in bottled drinking water. For example, about 10 chloramphenicol per ml of bottled mineral water in Canada was found. 2 -10 5 These bacteria are unlikely to cause illness, but high levels of bacteria in bottled water may pose a risk to vulnerable groups such as pregnant women, newborns, immunocompromised patients and the elderly. Demand for bottled water has grown steadily in recent years, making it the fastest growing segment of soft drinks worldwide.

[0006] However, the high consumption of single-use bottles has been linked to increased waste and soil contamination. Only a small fraction of plastic bottles are recycled. The environmental costs associated with bottled water have led to a societal push to adopt refillable bottles.

[0007] Refillable bottles are more environmentally friendly and cost-effective because consumers can refill them repeatedly. This ability to refill and reuse water bottles requires regular cleaning of the bottles. However, observing consumer behavior related to refillable water bottles shows that users regularly refill their water bottles without making a corresponding effort to clean them. In addition, the shape of refillable water bottles can hinder their cleaning.

[0008] Drinking straws are often exposed to the environment and repeatedly placed in the user's mouth, where they may become contaminated with microorganisms or other pathogens, thereby infecting or reinfecting the user.

[0009] Medical tubing used to deliver fluids such as oxygen, liquids or medications to a person may also become contaminated with microorganisms or other pathogens. In fact, in order to allow a person to move while using the medical tubing, a length of the medical tubing extends between the person and the dispensing station. Thus, the tubing can lie on the floor, on bed sheets or in contact with other people during normal use, thereby becoming a reservoir for microorganisms or other pathogens, which can then be transferred to the person administering the fluid, or to other people or surfaces.

[0010] Salmonella and Escherichia coli are among the most common pathogens in food and beverages, affecting millions of people each year, sometimes with serious and fatal consequences. Symptoms are fever, headache, nausea, vomiting, abdominal pain and diarrhea.

[0011] Listeria monocytogenes can also contaminate food and beverages. Infection with Listeria can cause miscarriage in pregnant women or death in newborns. Listeria has serious and sometimes fatal consequences for health, especially in infants, children and the elderly, and represents the most serious food infection for these groups, with a high mortality rate in the context of foodborne infections.

[0012] Staphylococcus aureus is responsible for acute suppurative infections that may occur in different parts of the body, such as the skin, skeletal system, respiratory system, urinary system, central nervous system. Some bacterial strains can also cause poisoning and various types of pathological manifestations due to their ability to produce some characteristic exotoxins. Antibiotic resistance is a very common feature of the Staphylococcus family (Staphylococcaceae), especially in so-called nosocomial infections that may be encountered in hospital environments. The cause of these infections is usually iatrogenic and is often found in the blood of subjects with prosthetic and intravascular implants. Due to widespread drug resistance, in many cases resistance to multiple drugs, these infections are a problem that is often difficult to solve; many antibiotic-resistant pathogens are now known and studied, including the so-called MRSA (methicillin-resistant Staphylococcus aureus).

[0013] Therefore, there is a need to provide hygienically safe tubular conduits suitable for use in the food and medical fields.

[0014] Application US20150209567 discloses a tubular catheter made of a polymeric material having an outer layer, an inner layer and an intermediate layer, wherein the outer layer and / or the inner layer incorporates an antimicrobial agent, such as silver. The silver may be in elemental or ionic state, in the form of nanoparticles or zeolites, and optionally in combination with zinc.

[0015] Antimicrobial peptides (AMPs) are produced in many tissues and cell types of organisms, such as plants, insects, amphibians and higher organisms, and are components of innate immunity. Their amino acid composition and structure-related chemical-physical properties allow them to selectively interact with the lipid bilayer of bacterial membranes, leading to microbial death. AMPs appear to have a high potential for activity against both Gram-negative and Gram-positive human pathogenic strains; moreover, unlike other drugs currently in use, these peptides do not easily select mutants and do not induce antibiotic resistance phenomena.

[0016] In recent years, many antimicrobial peptides have been identified by various techniques ranging from computer analysis to peptide library screening.

[0017] In particular, patent application WO2015038339 describes the structures of 753 7-12 amino acid peptides, which are shown to have anti-biofilm and / or immunomodulatory activity. Some of the peptides described therein have been tested for their ability to inhibit biofilms formed by Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, E. coli, Acinetobacter baumannii, Salmonella enterica ssp. Typhimurium, Burkholderia cenocepacia, Staphylococcus aureus and Pseudomonas aeruginosa; however, at the tested concentrations, these peptides showed no activity against planktonic cells of these bacteria. Herein, a decapeptide designated HE 10 is described, which has the sequence VRLIVRIWRR (SEQ ID NO: 33).

[0018] Patent application WO2019012158 discloses the use of some antimicrobial peptides (including IDR-1018-K6) as bacterial agents for preventing and / or treating contamination of products or surfaces by specific bacteria (i.e., Listeria monocytogenes). The document further discloses the use of antimicrobial peptides in treating infections caused by Listeria monocytogenes in subjects.

[0019] To date, the research conducted and the amount of data available in numerous databases (Wang, G., Li, X. and Wang, Z. (2016) APD3: the antimicrobial peptide database as a tool for research and education, Nucleic Acids Research 44, D1087-D1093) show that antimicrobial peptides can have different structures and target a variety of microorganisms. In addition, in many cases, peptides tend to present structures associated with activity after contact with the cell membrane. Based on the presence or absence of two key elements of secondary structure (α-helix and β-sheet), AMPs are generally divided into four major categories: (i) peptides with linear α-helical structure, which represent the largest and best studied group; (ii) peptides with linear extended structure (without α-helical or β-sheet elements); (iii) peptides containing β-sheets and (iv) peptides containing α-helical and β-sheet elements. Hundreds of different sequences have been identified from natural sources, and a large number of analogs and synthetic derivatives have been produced, and their size and diversity are constantly expanding (Johannes Koehbach and David J. Craik. The Vast Structural Diversity of Antimicrobial Peptides, Trends in Pharmacological Sciences, July 2019, Vol. 40, No. 7). Therefore, it seems that so far, there is no clear structure / function relationship for this type of antimicrobial molecule, making it difficult to predict their activity.

[0020] Most known AMPs are small in size, typically between 12 and 50 amino acid residues. Longer ones such as nisin (34 aa) or LL37 (37 aa) are at least partially structured, also due to their longer amino acid chains.

[0021] Although the antimicrobial effects of nisin have been known for decades, its mechanism of action still needs further investigation. This may be due to the fact that nisin acts through different mechanisms depending on the structural properties of the target bacterial membrane. Nisin itself is active only against Gram-positive bacteria, but its combination with treatments that disrupt the cell membrane makes it active against Gram-negative bacteria as well (Sukrita Punyauppa-path, Parichat Phumkhachorn, PongsakRattanachaikunsopon NISIN: PRODUCTION AND MECHANISM OF ANTIMICROBIAL ACTION, Int J Cur Res Rev | Vol 7 · Issue 2 · January 2015). Several studies have shown that some structural nisin (nisin) motifs are essential for the formation of "pores" in bacterial membranes, while other parts of the peptide contribute to the bactericidal effect by inhibiting cell wall synthesis. This suggests that nisin has at least two different mechanisms of action on bacteria (HBrotz and HG Sahl New insights into the mechanism of action of lantibiotics–diverse biological effects by binding to the same molecular target, Journal of Antimicrobial Chemotherapy, 2000, 46 1-6).

[0022] LL-37 also regulates its mechanism of action based on the structure of different lipids that form the cell membrane: it induces the formation of pores in unsaturated phospholipid bilayers and interferes with membrane function in the presence of saturated phospholipids, producing a fiber peptide-lipid superstructure rich in α-helical structure (Mahdi Shahmiri, Marta Enciso, Christopher G. Adda, Brian J. Smith, Matthew A. Perugini & Adam Mechler Membrane Core-Specific Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofibre Formation, Scientific Reports volume 6, Article number: 38184 (2016)).

[0023] It is therefore clear that larger peptides are generally likely to have greater folding variability and complexity, in other words, they are more likely to present a variety of secondary structures even in different parts of the amino acid chain. It is therefore difficult to understand and control the mechanism by which peptides with longer amino acid sequences are able to exert their biological activity, since there are more variables that influence and / or impair it. Moreover, in the case of functionalization of polymer surfaces using peptides through covalent bonds, longer amino acid sequences will statistically increase the sites at which the peptide can bind to the material of interest (PET; PVC; PL, etc.), making the conformation that the molecule can assume after forming a bond (or bonds at several points in the sequence) unpredictable and, therefore, also the possibility of maintaining antimicrobial activity.

[0024] On the other hand, small molecules make themselves more suitable for design and / or modification to maintain or amplify specific activity. In addition, the small size of antimicrobial peptides significantly reduces the cost of their synthesis and purification. However, shorter antimicrobial peptides have a lower probability of structure than longer antimicrobial peptides, so it is also difficult to predict their activity (Ralf Mikut, Serge Ruden, Markus Reischl, Frank Breitling, Rudolf Volkmer, Kai Hilpert. Improving short antimicrobial peptides despite elusive rules for activity Biochimica et Biophysica Acta 1858 (2016) 1024–1033).

[0025] In view of the above, it is clear that there is a need to provide tubular conduits suitable for use in the food and medical fields, which are functionalized with antimicrobial agents, particularly of the peptide type, which are capable of effective antimicrobial activity against a broad spectrum of microorganisms, including Gram-negative and Gram-positive bacteria, fungi and yeasts, and may also have antiviral effects. A further need is for such antimicrobial peptides to have an amino acid chain of medium length, which may be shorter than the currently known antimicrobial peptides. Another need is for such peptides to be synthesized and purified at as low a cost as possible. Summary of the invention

[0026] To meet these and other needs, the present inventors have investigated several antimicrobial agents suitable for functionalizing the outer and / or inner surfaces of tubular conduits made of various materials, such as polymeric materials, glass and metal, and have identified antimicrobial peptides (AMPs) that are particularly suitable for this purpose. These antimicrobial peptides consist of an amino acid sequence represented by the general formula (I). They are particularly suitable for the above-mentioned purposes because they have a broad spectrum of antimicrobial activity and are characterized by a relatively short amino acid sequence.

[0027] Example 1 in the experimental part below shows the synthesis of the RiLK1 peptide, which represents a peptide of general formula (I) for use within the scope of the present invention.

[0028] The RiLK1 peptide and all other AMP peptides of formula (I) share the fact that they contain the structural motif WXXXW and have similar hydrophobicity, hydrophilicity, amphipathicity, affinity, net charge, Bowman index and disordered conformational tendency, which indicates similar bactericidal properties (see Examples 5 and 6).

[0029] Examples 2a and 2b show that the RiLK1 peptide exhibits strong bactericidal activity against both Gram-negative bacteria (such as Salmonella typhimurium and Escherichia coli) and Gram-positive bacteria (such as Staphylococcus aureus and Listeria monocytogenes). In addition, it also exhibits effective antibacterial activity against fungi and yeasts (such as Aspergillus brasiliensis and Candida albicans) (Example 2c).

[0030] Example 3 shows that RiLK1 can bind to the polymer surface of a straw made of a polymer material with a binding yield of 17%, thereby producing a straw functionalized with an antimicrobial agent. In addition, the functionalized straw placed in water for 24 hours remained stable without releasing antimicrobial peptides.

[0031] As shown in Example 4, the straw made of a polymer material functionalized with the antimicrobial peptide RiLK1 exhibits bactericidal activity against Gram-negative bacteria (such as Salmonella typhimurium and Escherichia coli) and against Gram-positive bacteria (such as Staphylococcus aureus and Listeria monocytogenes).

[0032] Therefore, a first object of the present invention is a tubular catheter comprising an outer surface and an inner surface, wherein at least a portion of the outer surface and / or the inner surface is functionalized with at least one antimicrobial peptide consisting of the following formula (I). The at least one antimicrobial peptide is covalently linked to a reactive group present on the outer surface and / or the inner surface of the tubular catheter, or it is contained in a coating attached thereto.

[0033] The second object of the present invention is the use of the antimicrobial peptide composed of formula (I) for preventing tubular catheters from being contaminated by Gram-negative bacteria, Gram-positive bacteria, fungi, yeasts and / or viruses.

[0034] A third object of the present invention is a container, such as a bottle, a cutlery box or a jar, provided with a removable straw functionalized with an antimicrobial peptide consisting of formula (I), the function of which is to reduce the risk of contamination by pathogens. More specifically, the removable straw of the container of the present invention comprises an outer surface and an inner surface, wherein at least a portion of the outer surface and / or the inner surface is functionalized with at least one antimicrobial peptide of formula (I). BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1Dose response curves obtained with the RiLK1 peptide against S. aureus (A), L. monocytogenes (B), S. typhimurium (C) and E. coli (D) are shown; the abscissa axis shows peptide concentration (μM) and the ordinate axis shows % of viable cells, as described in Example 2a.

[0036] Figure 2a , Figure 2b , Figure 2c and Figure 2d For each test bacteria (i.e., Staphylococcus aureus, Listeria monocytogenes, Salmonella typhimurium, and Escherichia coli, respectively) Figure 2c and Figure 2d , it is necessary to correct the captions related to Salmonella typhimurium and Escherichia coli) shows photographic images of a control plate incubated with bacteria but without the addition of RiLK1 peptide (1), a plate incubated with bacteria and treated with RiLK1 peptide at a concentration below its MBC (2), and a plate incubated with bacteria and treated with RiLK1 peptide concentration corresponding to its MBC (3), as described in Example 2b.

[0037] Figure 3 Shown is a reverse phase chromatogram of the RiLK1 peptide present in the composition at time point = zero (line A) and a reverse phase chromatogram of the RiLK1 peptide remaining in the composition at time point = 24 hours (line B) obtained using a C18 column by an HPLC system as described in Example 3. The figure depicts the absorbance value of the RiLK1 peptide at 280 nm as a function of the elution time measured in minutes (min).

[0038] Figure 4 Shown are the % reduction in bacterial load expressed as CFU in liquid cultures of E. coli (A), S. typhimurium (B), and L. monocytogenes (C) into which the pipette was inserted for 4, 6, 8, and 24 hours of contact.

[0039] Figure 5 Shown is the % reduction in bacterial load expressed as CFU in tap water contaminated with Escherichia coli (A), Salmonella typhimurium (B) and Listeria monocytogenes (C) at a cell concentration of 150 CFU / mL in which a pipette was inserted for 4, 6, 8 and 24 hours of contact. DETAILED DESCRIPTION

[0040] A first object of the present invention is a tubular catheter comprising an inner surface and an outer surface, wherein at least a portion of the outer surface and / or the inner surface is functionalized with at least one antimicrobial peptide consisting of formula (I).

[0041] In a preferred embodiment, at least one antimicrobial peptide is covalently linked to a reactive group present on at least a portion of the outer surface and / or the inner surface of the tubular conduit; or, at least one antimicrobial peptide is contained in a coating attached to at least a portion of the outer surface and / or the inner surface of the tubular conduit.

[0042] As mentioned above, at least one antimicrobial peptide is composed of an amino acid sequence represented by formula (I) shown below or a salt or solvate thereof:

[0043] X1LX2WVX3IWX4X5 (I)

[0044] wherein X1, X2, X3, X4 and X5 are independently selected from K and R and wherein each amino acid is independently in the D or L configuration.

[0045] It should be noted that all amino acid sequences represented in this specification are represented by formulas oriented from left to right in the conventional direction (ie, from the amino terminus to the carboxyl terminus).

[0046] According to a preferred embodiment, the amino acids in the above formula (I) are all in D configuration or L configuration.

[0047] According to another preferred embodiment, in the above formula (I), at least one of X1, X3, X4 and X5 has the meaning of R; more preferably, X4 and X5 have the meaning of R; still more preferably, X3, X4 and X5 have the meaning of R; even more preferably, X1, X3, X4 and X5 have the meaning of R.

[0048] In another preferred embodiment, X2 has the meaning of K.

[0049] In another preferred embodiment, at least one of X1, X3, X4 and X5 has the meaning of R and X2 has the meaning of K; more preferably, X4 and X5 have the meaning of R and X2 has the meaning of K; still more preferably, X3, X4 and X5 have the meaning of R and X2 has the meaning of K; even more preferably, X1, X3, X4 and X5 have the meaning of R and X2 has the meaning of K.

[0050] The following amino acid sequence is particularly preferred:

[0051] RLX2WVRIWX4X5, RLX2WVRIWRX5, RLX2WVRIWX4K, RLKX2WVRIWKK, X1LKWVX3IWRR, X1LKWVRIWRR, RLKWVX3IWRR,

[0052] wherein X1, X2, X3, X4 and X5 are independently selected from K and R and wherein each amino acid is independently in the D or L configuration.

[0053] The following specific amino acid sequences are further preferred:

[0054] RLKWVRIWRR(SEQ ID NO:1),KLRWVRIWRR(SEQ ID NO:2),RLRWVRIWRR(SEQ ID NO:3),KLKWVRIWRR(SEQ ID NO:4),RLKWVKIWRR(SEQ ID NO:5),KLRWVKIWRR(SEQ ID NO:6),RLRWVKIWRR(SEQ ID NO:7), KLKWVKIWRR (SEQ ID NO:8), RLKWVRIWKR (SEQ ID NO:9), KLRWVRIWKR (SEQ ID NO:10), RLRWVRIWKR (SEQ ID NO:11), KLKWVRIWKR (SEQ ID NO:12), RLKWVKIWKR (SEQ ID NO:13), KLRWVKIWKR (SEQ ID NO:14), RLRWVKIWKR (SEQ ID NO:15), KLKWVKIWKR (SEQ ID NO:16), RLKWVRIWRK (SEQ ID NO:17), KLRWVRIWRK (SEQ ID NO:18), RLRWVRIWRK (SEQ ID NO:19), KLKWVRIWRK (SEQ ID NO:20), RLKWVKIWRK (SEQ ID NO:21), KLRWVKIWRK (SEQ ID NO:22), RLRWVKIWRK (SEQ ID NO:23), KLKWVKIWRK (SEQ ID NO:24), RLKWVRIWKK (SEQ ID NO:25), KLRWVRIWKK (SEQ ID NO:26), RLRWVRIWKK (SEQ ID NO:27), KLKWVRIWKK (SEQ ID NO:28), RLKWVKIWKK (SEQ ID NO:29), KLRWVKIWKK (SEQ ID NO:30), RLRWVKIWKK (SEQ ID NO:31), KLKWVKIWKK (SEQ ID NO:32),

[0055] wherein each amino acid is independently in the D or L configuration.

[0056] The peptide having the sequence SEQ ID NO: 1 is the peptide indicated as "RiLK1" within the scope of the present description.

[0057] In the context of the present invention, the term "solvate" or "solvate" refers to a complex of a peptide of the present invention with a solvent in which a synthetic reaction is carried out or in which it is precipitated or crystallized. For example, a complex with water is called a "hydrate."

[0058] Salts and solvates suitable for the purposes of the present invention are those which do not cause changes in the conformation or stability of the peptides according to the invention and therefore do not interfere with their biological activity.

[0059] Preferred salts according to the present invention are pharmaceutically acceptable salts that do not cause conformational or stability changes in the peptides of the present invention. As illustrative and non-limiting examples, pharmaceutically acceptable acid addition salts include salts formed by hydrochloric acid, hydrobromic acid, acetic acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succinic acid, perchloric acid, fumaric acid, maleic acid, glycolic acid, lactic acid, salicylic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid and isethionic acid. Other acids, such as oxalic acid, although not pharmaceutically acceptable per se, can be used as intermediates for obtaining peptides of the present invention and pharmaceutically acceptable salts thereof. Acceptable alkali salts include ammonium salts, alkali metal salts (such as potassium salts and sodium salts), alkaline earth metal salts (such as calcium salts and magnesium salts) and salts formed with organic bases (such as dicyclohexylamine and N-methyl-D-glucosamine).

[0060] Preferably, according to the invention, the tubular conduit is a drinking straw or a medical tube; more preferably, it is a drinking straw which is incorporated in and optionally removable from a container, such as a bottle, cutlery box or can.

[0061] In a preferred embodiment, the tubular conduit is a straw for food or drink.

[0062] Preferably, according to the present invention, the at least one antimicrobial peptide present on at least a portion of the outer surface and / or the inner surface of the tubular conduit has a molar amount of 1 to 10 nmol x cm 2 surface, more preferably 1.5 to 3 nmol×cm 2 surface.

[0063] According to the present invention, the material of the tubular conduit is preferably a polymer; by way of illustrative and non-limiting example, suitable polymers are styrene block copolymers, polyolefin blends, elastomer blends, thermoplastic polyurethanes, thermoplastic copolyesters, thermoplastic polyamides, polypropylene, polyethylene, high-density polyethylene, low-density polyethylene, polyethylene terephthalate, polyethylene 1,4-cyclohexanedimethylene terephthalate, polyethylene 2,6-naphthalate dibenzoate, polyolefins, polyvinylidene fluoride, polyethylene 2,6-naphthalate, acrylonitrile butadiene styrene, polyvinyl chloride, polyether block amides, biodegradable polymers and mixtures thereof. More preferably, the polymer material is a biodegradable polymer, such as polylactic acid (PLA), polybutylene adipate-co-terephthalate (PBAT), polycaprolactone (PCL), modified starch ( ) or polyglycolic acid (PGA), polybutylene succinate (PBS), polyhydroxyalkanoate (PHA) ( Even more preferably, the polymer material is polylactic acid.

[0064] The inventors have studied different types of polymers and found that PLA is particularly suitable for functionalization for the purposes of the present invention. PLA is a thermoplastic polymer belonging to the aliphatic polyester family with properties similar to polyethylene terephthalate (PET). It is derived from sugar, so it is a product derived from 100% natural resources and therefore has zero environmental impact. PLA can be easily processed using conventional machines for thermoforming and uniaxial or biaxial extrusion of polymer films, by injection and by foaming. PLA is 100% biodegradable and compostable. PLA is stable under standard environmental conditions (20°C, 1Atm) and degrades by hydrolysis at temperatures above 65°C and humidity above 20%, so the biodegradation time can vary greatly depending on environmental conditions. At 65°C and 95% humidity (which are standard conditions in a normal composting station), PLA-based products degrade in about 50 days. PLA-based products degrade within 15 months if left on the ground, within 24 months if burned, and within 48 months if placed in water.

[0065] Preferably, the tubular conduit according to the invention is a drinking straw or medical tube made of PLA; more preferably, it is a drinking straw made of PLA and is incorporated into and optionally removable from a container, such as a bottle, cutlery box or can.

[0066] As mentioned above, one embodiment of the present invention is one in which at least one antimicrobial peptide is covalently attached to a reactive group present on at least a portion of the outer surface and / or the inner surface of the tubular conduit.

[0067] In this case, the N-terminal amino group of the peptide is covalently linked to at least one chemical group present on at least a portion of the outer surface and / or inner surface of the tubular conduit, the at least one chemical group preferably being selected from a carboxyl group, an excited hydroxyl radical, an activated alkoxy group or an activated aldehyde or ketone group.

[0068] In fact, the present inventors have found that when the N-terminal group of the peptide is covalently linked to a chemical group present on the surface of a tubular catheter, the peptide retains bactericidal activity despite its locked conformation and that this bactericidal activity remains stable over a long period of time.

[0069] Techniques for binding peptides to solid supports are known to those skilled in the art and vary depending on the material used. The surface functionalization methods mainly used are chemical or physical methods.

[0070] For example, in the case of materials with metal (gold, silver, platinum) or semiconductor (titanium, zinc, tin, zirconium, germanium) surfaces, a silanization process can be used. For example, this involves reacting the material to be treated with a mixture of sulfuric acid (H2SO4) and oxygen peroxide (H2O2), which are able to activate the aforementioned surface by creating bonds of surface atoms or hydroxyl groups (-OH) that can be easily replaced by more stable bonds (such as Si-C or Au-S). After treatment with a silanizing agent (such as aminopropyldimethylethoxysilane or aminopropyltriethoxysilane) and with a compound having two functional groups that can form a peptide covalent bond with the amino group of the peptide (such as glutaraldehyde or disuccinimide), the activated surface can covalently bind the target peptide. These treatments are typical aqueous solution chemistry, and therefore they are called wet processes, which is advantageous because they do not require special technical equipment, but only require (preferably rigid) materials that can be wetted and dried without difficulty.

[0071] In the case of plastic or polymer surfaces, they can be activated for attachment of peptides of interest by applying wet processes (such as those described above) and dry processes.

[0072] Wet activation, typically aqueous chemistry, is generally advantageous because it does not require special technical equipment, but only a (preferably rigid) material that can be wetted and dried without difficulty. The activated surface is then reacted with a silanizing agent (e.g. aminopropyldimethylethoxysilane or aminopropyltriethoxysilane) and with a compound having two functional groups capable of forming a peptide covalent bond with the amino groups of the peptide (e.g. glutaraldehyde or bissuccinimide).

[0073] Dry activation is based on the interaction between the surface to be treated and electromagnetic radiation (such as laser, ultraviolet radiation, gamma ray) or ionized gas (gas plasma). The interaction between the polymer surface and the electromagnetic radiation leads to surface activation, thereby allowing the surface itself to be chemically modified subsequently. Similar operating principles are also applicable to the activation of polymer surfaces by gas plasma treatment. This method is particularly advantageous because the temperature of the treated material will not reach a high value relative to room temperature due to the cold plasma. This method requires low pressure (0.1-100 Pa) and the presence of working gas (usually N2, O2 or Ar, CF4). [Hegemann, Dirk, Herwig Brunner, and Christian Oehr. "Plasmatreatment of polymers for surface and adhesion improvement." Nuclear instruments and methods in physics research section B: Beam interactions with materials and atoms 208 (2003): 281-286].

[0074] As mentioned above, a further embodiment of the present invention is one in which the at least one antimicrobial peptide is contained in a coating attached to at least a portion of the outer surface and / or the inner surface of the tubular conduit.

[0075] In this case, the functionalization process involves depositing a liquid antimicrobial composition containing the antimicrobial peptide onto a surface portion of the tubular catheter, followed by drying the liquid antimicrobial composition. The liquid antimicrobial composition may optionally contain a film former that forms a film on the surface of the antimicrobial catheter that facilitates the persistence of the peptide on the surface. Thus, the above-mentioned coating may contain a film-forming polymer.

[0076] Preferably, the concentration of the at least one antimicrobial peptide in the liquid antimicrobial composition is 10 to 100 μM, more preferably 20 to 80 μM, 30 to 60 μM, 40 to 60 μM.

[0077] Preferably, the incubation time of the tubular catheter in the liquid antimicrobial composition containing at least one antimicrobial peptide is 18 to 36 hours, more preferably 20 to 30 hours.

[0078] As described above, the features of the tubular conduit according to the present invention are suitable for preventing contamination by Gram-negative bacteria, Gram-positive bacteria, fungi, yeasts and / or viruses.

[0079] Therefore, a second object of the present invention is the use of an antimicrobial peptide as defined above for preventing contamination of tubular catheters by Gram-negative bacteria, Gram-positive bacteria, fungi, yeasts and / or viruses.

[0080] In the present context, the Gram-negative bacteria are preferably selected from Campylobacter, such as, for example, Campylobacter coli, Campylobacter concisus, Campylobacter jejuni, Campylobacter C. rectus; Arcobacter, such as, for example, Arcobacter butzleri, Arcobacter cryaerophilus; Citrobacter, such as, for example, Citrobacter amalonaticus, Citrobacter braakii, Citrobacter farmeri, Citrobacter freundii, Citrobacter gillenii, Citrobacter spp. koseri; Enterobacter, such as, for example, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae, Enterobacter cowanii, Enterobacter gergoviae; Escherichia, such as, for example, Escherichia coli; Klebsiella; Morganella, such as, for example, Morganella Morganii; Proteus, such as, for example, Proteus vulgaris, Proteus mirabilis; Shigella, such as, for example, Shigella dysenteriae. dysenteriae); Salmonella, such as, for example, Salmonella typhi, Salmonella typhimurium;Yersinia, such as, for example, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica; Serratia marcescens; Aerobacter aerogenes; Enterobacter sakazakii; Acinetobacter, such as, for example, Acinetobacter baumannii, Acinetobacter beijerinckii, Acinetobacter bereziniae, Acinetobacter boissieri; Moraxella, such as, for example, Moraxella catarrhalis (the same name as Branhamella catarrhalis) catarrhalis); Neisseria, such as, for example, Neisseria meningitidis; Haemophilus, such as, for example, Haemophilus influenzae; Pasteurella, such as, for example, Pasteurella multocida; Pseudomonas, such as, for example, Pseudomonas aeruginosa; Vibrio, such as, for example, Vibrio cholerae, Vibrio fischeri, Stenotrophomonas maltophilia, and combinations thereof. More preferably, the Gram-negative bacteria are selected from Salmonella typhimurium and Escherichia coli.;

[0081] The gram-positive bacteria are preferably selected from the group consisting of Actinobacteria, such as, for example, Tropheryma whipplei; Bacillus; Carnobacterium; Clostridium; Corynebacterium diphtheria; Enterococcus, such as, for example, Enterococcus faecalis; Gardnerella vaginalis; Lactobacillus; Lactococcus; Listeria, such as, for example, Listeria monocytogenes; Micrococcus; Staphylococcus, such as, for example, Staphylococcus aureus; aureus); Streptococcus, such as, for example, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, and combinations thereof. More preferably, the Gram-positive bacteria is selected from Listeria monocytogenes and Staphylococcus aureus.

[0082] The fungus is preferably Aspergillus brasiliensis and the yeast is preferably Candida albicans.

[0083] The viruses are preferably viruses equipped with a capsid and an additional coating called pericapsid; they can be DNA or RNA viruses. Preferably, the virus is an adenovirus, a papillomavirus (HPV), a herpes virus, a coronavirus, an influenza virus, a cytomegalovirus (CMV), HIV or an Ebola virus.

[0084] The following examples are provided for illustrative purposes only and do not limit the scope of the present invention as defined in the appended claims.

[0085] Example

[0086] Example 1 - Synthesis of RiLK1 peptide

[0087] The RiLK1 peptide having the sequence RLKWVRIWRR (SEQ ID NO: 1) was synthesized by solid phase peptide synthesis using the protecting group fluoromethoxycarbonyl (Fmoc).

[0088] Rink-amide MBHA resin with a degree of substitution of 0.5 mmol / g was used as a solid support. The resin had a linker that provided an amide bond and released the peptide amidated at the C-terminus.

[0089] At the end of the synthesis, the protecting groups were removed by treatment with 40% (v / v) piperidine in DMF, while desorption from the resin and removal of the protecting groups from the amino acid side chains was achieved by treatment with an acidic solution consisting of 95% trifluoroacetic acid, 2.5% triisopropylsilane and 2.5% H2O (v / v / v).

[0090] After detachment from the solid support, the peptide was precipitated in cold ether at -20°C. The sample was centrifuged at 3500 rpm for 5 minutes to collect the precipitate. The precipitate was dissolved in a mixture of CH3CN / H2O (95:5), frozen and lyophilized.

[0091] This procedure can be used to synthesize all AMP peptides used in the present invention.

[0092] Example 2 - Analysis of bactericidal activity of RiLK1

[0093] Example 2a - Evaluation of the ability to have 50% bacterial growth inhibition (IC 50 ) concentration

[0094] The bactericidal activity of the RiLK1 peptide was evaluated against Gram-positive (Listeria monocytogenes LM2 and Staphylococcus aureus) and Gram-negative (Salmonella typhimurium and Escherichia coli) pathogens.

[0095] For the four bacterial species, strains selected, authenticated and characterized as shown in Tables 1 and 2 below were used.

[0096] The inhibitory effect on the growth of bacteria by 50% (IC 50 ) of the RiLK1 peptide were evaluated.

[0097] Standard deviations were obtained from triplicate experiments for each peptide dilution, and IC was determined using GraphPad Prism version 6.00 (Graph-Pad Software, La Jolla California USA). 50 .

[0098] All bactericidal activity assays were performed using 2-3 log CFU (colony forming units), which represents a realistic approximation of the level of contamination that may be contained in tubular catheters intended for food or medical use.

[0099] Staphylococcus aureus

[0100] A control stock suspension was prepared in which 10 3 CFU of S. aureus was inoculated into 10 ml BPW. A 5 mM stock solution of RiLK1 peptide was then prepared and serially diluted (100 to 1 μM) in BPW and inoculated into 10 3 CFU of S. aureus were then incubated for 6 hours at 37° C. At the same time, control samples were prepared and treated in the same manner but without the addition of peptides.

[0101] Pour 50 μl of each bacterial suspension into blood agar or rabbit plasma fibrinogen agar dishes and incubate at 37 °C for 20 h.

[0102] All experimental conditions studied used the plate count method to estimate the bactericidal activity of the peptides. Specifically, the number of colonies grown on agar plates inoculated with bacterial suspensions in the absence or presence of individual peptide dilutions was counted and compared. Standard deviations were determined using statistical software.

[0103] Listeria monocytogenes

[0104] A control stock suspension was prepared in which 10 3 CFU of L. monocytogenes was inoculated in 10 ml of 1 / 2 Fraser broth, and the suspension was serially diluted (100 to 0.01 μM). A 5 mM stock solution of the peptide in DMSO was then prepared and serially diluted (100 to 0.01 μM) in Fraser broth and inoculated with 10 3 CFU of Listeria monocytogenes were then incubated at 37°C for 6 hours. At the same time, control samples were prepared and treated in the same way but without the addition of peptides. 50 μl of each bacterial suspension was inoculated on different culture plates: blood agar and ALOA (Oxoid, Basingstoke, UK), and then incubated at 37°C for 24-48 hours. Each dilution series included a control plate inoculated with DMSO without peptide and a control plate inoculated with bacteria alone.

[0105] Salmonella Typhimurium

[0106] A control stock suspension was prepared in which 10 3CFU of S. typhimurium were inoculated in 10 ml BPW (Oxoid, Basingstoke, UK). A 5 mM stock solution of the peptide was then prepared and serially diluted (100 to 1 μM) in BPW and inoculated into 10 3 CFU of S. typhimurium were then incubated for 6 hours at 37° C. 50 μl of each bacterial suspension was inoculated in blood agar or chromogenic agar (Oxoid, Basingstoke, UK) and incubated for 20 hours at 37° C. Each dilution series included a control plate inoculated with DMSO without peptide and a control plate inoculated with bacteria alone.

[0107] Escherichia coli

[0108] A control stock suspension was prepared in which 10 3 CFU of E. coli were inoculated into 10 ml BPW (Oxoid, Basingstoke, UK). A 5 mM stock solution of the peptide was then prepared and serially diluted in BPW (100 to 1 μM) and inoculated into 10 3 coli were inoculated with 50 μl of each bacterial suspension and then incubated for 6 hours at 37° C. 50 μl of each bacterial suspension was inoculated on a petri dish with blood agar or chromogenic agar (Oxoid, Basingstoke, UK) and incubated for 20 hours at 37° C. Each dilution series included a control plate inoculated with DMSO without peptide and a control plate inoculated with bacteria alone.

[0109] Figure 1 Dose-response curves obtained with the RiLK1 peptide against S. aureus (A), L. monocytogenes (B), S. typhimurium (C), and E. coli (D) are depicted.

[0110] Based on the obtained dose-response curves, the IC against the above strains was determined. 50 Value (peptide concentration capable of inhibiting 50% bacterial growth).

[0111] The data reported in Table 1 show that the RiLK1 peptide exhibited strong bactericidal activity against all tested bacteria (IC 50 <2 μM); in particular, stronger bactericidal activity was observed against Salmonella typhimurium, Escherichia coli, and Listeria monocytogenes (IC 50 <1.5 μM), and even stronger bactericidal activity was observed against Listeria monocytogenes (IC 50 0.46 μM).

[0112] Table 1

[0113]

[0114] Example 2b - Evaluation of Minimum Bactericidal Concentration (MBC)

[0115] The minimum bactericidal concentration (MBC), the lowest concentration of antimicrobial agent that inhibits 99.9% bacterial growth on the plate, was evaluated as described in Bílikova et al, (2015, Peptides 68:190–196).

[0116] The data reported in Table 2 below show that the RiLK1 peptide exhibited strong bactericidal activity against all tested bacteria (MBC < 20 μM); in particular, relatively strong bactericidal activity was observed against Listeria monocytogenes, Salmonella typhimurium and Escherichia coli (MBC < 5 μM), and even stronger bactericidal activity was observed against Listeria monocytogenes and Escherichia coli (MBC 2 μM).

[0117] Table 2

[0118]

[0119] Figure 2a The images in represent photographic images of (1) a control plate incubated with S. aureus but without the addition of RiLK1 peptide, (2) a plate incubated with S. aureus and treated with 2 μM RiLK1 peptide, and (3) a plate incubated with S. aureus and treated with 16 μM RiLK1 peptide, indicating that at a concentration of 16 μM, the peptide was able to inhibit almost 100% bacterial growth.

[0120] Figure 2b The images in represent photographic images of (1) a control plate incubated with Listeria monocytogenes but without the addition of RiLK1 peptide, (2) a plate incubated with Listeria monocytogenes and treated with 0.8 μM RiLK1 peptide, and (3) a plate incubated with Listeria monocytogenes and treated with 2 μM RiLK1 peptide, which shows that at a concentration of 2 μM, the peptide is able to inhibit almost 100% of bacterial growth.

[0121] Figure 2c The images in represent photographic images of (1) a control plate incubated with Salmonella typhimurium but without the addition of RiLK1 peptide, (2) a plate incubated with Salmonella typhimurium and treated with 0.8 μM RiLK1 peptide, and (3) a plate incubated with Salmonella typhimurium and treated with 2 μM RiLK1 peptide, indicating that at a concentration of 2 μM, the peptide was able to inhibit almost 100% bacterial growth.

[0122] Figure 2dThe images in represent photographic images of (1) a control plate incubated with E. coli but without the addition of RiLK1 peptide, (2) a plate incubated with E. coli and treated with 0.8 μM RiLK1 peptide, and (3) a plate incubated with E. coli and treated with 2 μM RiLK1 peptide, indicating that at a concentration of 2 μM, the peptide was able to inhibit almost 100% bacterial growth.

[0123] Example 2c - Activity analysis against fungi and yeasts

[0124] Evaluation of RiLK1 peptide concentrations capable of inhibiting the growth of the fungus Aspergillus brasiliensis

[0125] The antifungal activity of the RiLK1 peptide was determined against Aspergillus brasiliensis. For this purpose, a stock culture was prepared in which 10 5 CFU of Aspergillus brasiliensis were inoculated in 10 ml of buffered peptone water. A reference strain (ATCC 9341) was used for this fungal species. The culture was incubated with the RiLK1 peptide at a concentration of 25 μM at 37° C. for 6 hours.

[0126] At the same time, control samples were incubated without addition of peptide. 100 μl of the samples thus prepared were inoculated on DG18 plates (Dichloran 18% glycerol agar - ISO 21527-2) and incubated at 25°C for 7 days.

[0127] All experimental conditions studied used the plate count method to estimate the fungicidal activity of the peptides. Specifically, the number of colonies grown on agar plates inoculated with fungal suspensions in the absence or presence of a single peptide dilution was counted and compared. The standard deviation of three incubations for each plate was determined using statistical software. The minimum fungicidal concentration (MFC) was evaluated as described in Bílikova et al, (2015, Peptides 68: 190–196), i.e., the lowest concentration of antifungal agent that could inhibit fungal growth on the plate by 99.9%.

[0128] The RiLK1 peptide has strong fungicidal activity against the tested fungi, with MFC values ​​less than or equal to 25 μM. It should be noted that the peptide IDR-1018-K6 (the subject of patent WO2019012158) was not active against the same fungi under the same experimental conditions, with a 0Log reduction in fungal load after treatment, compared to the significant reduction induced by RiLK1 (5Log reduction).

[0129] Evaluation of RiLK1 peptide concentrations capable of inhibiting the growth of the yeast Candida albicans

[0130] The inhibitory activity of the RiLK1 peptide was determined against the yeast Candida albicans. A stock culture was prepared in which 10 5CFU of Candida albicans was inoculated in 10 ml of buffered peptone water. A reference strain (ATCC 14053) was used for this species. The culture was incubated at 37°C for 6 hours with a concentration of 25 μM of the RiLK1 peptide. At the same time, a control sample was incubated without the addition of peptide. 100 μl of the sample thus prepared was inoculated on a DG18 plate (Dichloran 18% glycerol agar-ISO21527-2) and incubated at 25°C for 7 days.

[0131] All experimental conditions studied used the plate count method to estimate the antifungal activity of the peptides. Specifically, the number of colonies grown on agar plates inoculated with cultures in the absence or presence of individual peptide dilutions was counted and compared. The standard deviation of three incubations for each plate was determined using statistical software. The minimum fungicidal concentration (MFC) was evaluated as described in Bílikova et al, (2015, Peptides 68: 190–196), i.e., the lowest concentration of antifungal agents that could inhibit fungal growth on the plate by 99.9%.

[0132] The RiLK1 peptide has strong antifungal activity against Candida albicans, with MFC values ​​less than or equal to 25 μM. It should be noted that, as shown in Table 3, the peptide IDR-1018-K6 (described in patent application WO2019012158) showed low efficiency against the same fungus under the same experimental conditions, with post-treatment reducing the fungal load by 1.0 Log compared to the significant reduction induced by RiLK1 (5 Log reduction).

[0133] Table 3

[0134]

[0135] Example 3 - Functionalization of straws with antimicrobial peptides

[0136] Polylactic acid (PLA) straws were prepared by extrusion using equipment from Hangzhou Depai Machinery Co., Ltd. and functionalized with the RiLK1 peptide prepared in Example 1. Specifically, the straws were first dry activated by plasma treatment (50-100 W, 5 minutes) using oxygen plasma (Atmospheric plasma surface treatment machine with three rotating nozzles-Shenzhen Fangrui Technology Co., Ltd.), followed by incubation in a 50 μM RiLK1 solution for 24 hours. At the end of the process, the peptide was covalently linked to the reactive groups present on the surface of the PLA straws.

[0137] Figure 3Reverse phase chromatograms obtained using a C18 column and HPFC system are shown. Line A shows the absorption peak of the RiFK1 peptide present in the composition at time point = zero, i.e. before incubation with the activated polylactic acid straws. Line B shows the absorption peak of the RiFK1 peptide remaining in the composition at time point = 24 hours, i.e. after 24 hours of incubation with the straws. After 24 hours of incubation, the yield of the bond between the RiFK1 peptide and the straws can be estimated and found to be 17%. It is known that the surface area of ​​the functionalized straws is 11.304 cm 2 , the number of moles of surface-bound peptide was calculated and found to be 2.25 nmol × cm 2 straw.

[0138] After the pipettes functionalized with the RiFK1 peptide were placed in water for 24 h, reverse phase chromatography on a C18 column by an HPFC system showed that the peptide was not released at all in water.

[0139] Example 4 - Analysis of bactericidal activity of straws functionalized with antimicrobial peptides

[0140] From 10 1 –10 2 Starting with CFU (colony forming unit) values, the functionalized straws described in Example 3 were tested against Escherichia coli (A), Salmonella typhimurium (B) and Listeria monocytogenes (C); effectiveness was assessed at 4, 6, 8 and 24 hours.

[0141] Figure 5 The graph in shows the insertion of the straws into a culture broth with an average of 10-100 CFU / ml. Up to 4 hours, no reduction in CFU was observed because the concentration of the pathogen was still too low. At 6 hours, the functionalized straws exerted an antimicrobial effect against E. coli (100% reduction), S. typhimurium (99% reduction), and L. monocytogenes (73% reduction). Up to 6 hours, the functionalized straws still exerted an antimicrobial effect against E. coli (25% reduction). After 6 hours, the straws had zero bactericidal activity against S. typhimurium and L. monocytogenes at 8 and 24 hours.

[0142] The diagram in Figure 6 shows a realistic scenario of inserting a straw into drinking water contaminated with 15-150 CFU of pathogens / ml.

[0143] In this case, since the liquid was not a culture broth, the growth of pathogens was much less, while the functionalized straws showed bactericidal activity against Salmonella typhimurium (95% reduction) and Listeria monocytogenes (99% reduction) for up to 24 hours, and against Escherichia coli for up to 8 hours (81.5% reduction). In this regard, it should be considered that if the straw is integrated into a container, bottle or cutlery box for drinking water, this container is usually emptied and / or refilled within 8 / 12 hours.

[0144] Furthermore, it is clear from the above data that the functionalized straw is a device that is able to disinfect water by causing a decline in Listeria and Salmonella, and it remains effective against Listeria and Salmonella even after 24 hours.

[0145] As shown by the data reported in Examples 2a and 2b, respectively, the RiLK1 peptide, which is representative of the peptides used in the present invention, has a strong bactericidal activity against all tested bacteria (IC 50 <2 μM; MBC <20 μM).

[0146] As shown in Example 3, the RiLK1 peptide, which represents the peptide used in the present invention, can bind to the polymer surface of PLA straws with a binding yield of 17%, producing polymer straws functionalized with antimicrobial peptides; the functionalized straws remain stable in water for 24 hours and do not release antimicrobial peptides.

[0147] As shown in Example 4, PLA straws functionalized with the antimicrobial peptide RiLK1 and inserted into drinking water contaminated with pathogens showed bactericidal activity against Gram-negative bacteria such as Salmonella typhimurium and Escherichia coli and against Gram-positive bacteria such as Listeria monocytogenes. In particular, the functionalized straws had bactericidal activity against Salmonella typhimurium (95% reduction) and Listeria monocytogenes (99% reduction) for up to 24 hours, and bactericidal activity against Escherichia coli for up to 8 hours (81.5% reduction).

[0148] In summary, the experimental data reported above indicate that tubular catheters made of polymeric materials, whose outer and / or inner surfaces are functionalized with the specific antimicrobial peptides used in the present invention, are particularly suitable for use in the food and medical fields to prevent contamination by Gram-negative and / or Gram-positive bacteria.

[0149] Therefore, the functionalization with specific antimicrobial peptides used in the present invention has useful applications in the food and medical fields, for example, for preventing contamination on the surface of straws, preferably on the surface of straws that are incorporated and optionally removable from bottles.

[0150] Functionalization with specific antimicrobial peptides used in the present invention may also be usefully applied in the sterilization of liquid foods or beverages, such as water, which are consumed through a straw, preferably through a straw that is incorporated in the bottle and optionally removable from the bottle.

[0151] The antimicrobial peptides used in the present invention have the added advantage of selectively interacting with the lipid bilayer of the bacterial membrane, leading to the death of the microorganism, and the added advantage of not being prone to selecting mutants and not inducing antibiotic resistance phenomena.

[0152] The polymers used in the present invention have the added advantage of being derived from 100% natural resources and therefore having zero impact on the environment and being 100% biodegradable and compostable.

[0153] Example 5: Analysis of bactericidal activity of other AMP peptides used in the present invention

[0154] Other AMP peptides used in the present invention, in particular the RiLK31 peptide (RLRWVKIWKK, SEQ ID NO: 31) and the RiLK3 peptide (RLRWVRIWRR, SEQ ID NO: 3), were tested for their bactericidal activity. Bactericidal activity was expressed as the percentage of viable cells in terms of CFU (colony forming units) in bacterial samples exposed to each peptide compared to control bacterial samples in the absence of the peptide. All tests were performed using the same peptide concentration, corresponding to 15 μM. The results are shown in Table 4.

[0155] Table 4

[0156] Peptides Escherichia coli staphylococcus salmonella Listeria RiLK 100% 96.9% 100% 99.5% RiLK31 100% 83% 100% 98.8% LRQ 100% 96% 100% 99%

[0157] Table 4 shows that the AMP peptides further tested had bactericidal activity comparable to that of the RiLK1 peptide used as a representative peptide in Experiments 1-4 of the present specification.

[0158] Example 6: Characterization of other AMP peptides used in the present invention by computational analysis and comparison with the prior art HE10 peptide

[0159] In bioinformatics, sequence alignment is a method of organizing DNA, RNA, or protein sequences to identify regions of similarity that may arise from functional, structural, or evolutionary relationships between the sequences. Aligned sequences of amino acid residues are usually represented as rows in a matrix [Analysis Tool Web Services from the EMBL-EBI. (2013) McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, Lopez R. Nucleic acids research 2013 Jul; 41 (Web Server issue): W597-600 doi: 10.1093 / nar / gkt376; Principles and Methods of Sequence Analysis-Sequence-Evolution-Function-NCBI Bookshelf (Chapter 4) Koonin EV, Galperin MY. Sequence-Evolution-Function: Computational Approaches in Comparative Genomics. Boston: Kluwer Academic; 2003; Hans G. Boman (1995). Peptide antibiotics and their role in innate immunity.Annu.Rev.Immunol.1995.13:61-92]. Multiple sequence alignments highlight similar regions that may be associated with specific features, i.e., structural / functional preferences that are more conserved than others.

[0160] In a protein sequence alignment, the degree of similarity between amino acids occupying specific positions in the sequence can be interpreted as an approximate measure of specific conserved regions or motifs in the sequence. The absence of substitutions or the presence of only highly conservative substitutions (i.e., substitutions of amino acids whose side chains have similar biochemical properties) in a specific region of the sequence indicates that the region may have structural or functional importance [Hans G. Boman (1995). Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 1995. 13: 61-92; Markéta Pazderková, Petr Malo, Vlastimil Zíma, Katerina Hofbauerová, Vladimír Kopecky Jr., Eva Pazderka,Václav Cerovsky and Lucie Bednárová(2019).Interaction of Halictine-RelatedAntimicrobial Peptides with Membrane Models.Int.J.Mol.Sci.,20,631;doi:10.3390 / ijms20030631;Igor Zelezetsky,Alessandro Tossi(2006). Alpha-helicalantimicrobial peptides—Using a sequence template to guide structure–activityrelationship studies. Biochimica et Biophysica Acta 1758:1436–1449; Yang Wang, Jianbo Chen, Xin Zheng, Xiaoli Yang, Panpan M, Ying Cai, Bangzhi Zhang and Yuan Chena (2014). Design of novel analogues of short antimicrobial peptide anoplinwith improved antimicrobial activity.J.Pept.Sci.;20:945–951.DOI 10.1002 / psc.2705].

[0161] The presence of identical amino acid residues at different positions in two amino acid sequences is not a gain but rather leads to a decrease in the similarity score between the two peptides because it results in significant structural and functional changes.

[0162] When comparing two peptides, the correct way to identify variations and define similarity is to align the two sequences. This means placing one sequence on top of the other so that it is easier to highlight which positions are identical and which are different. Once the alignment is done, two quantitative parameters can be extracted from each pairwise comparison, namely identity and similarity. Identity defines the percentage of amino acids in the alignment that directly match. Similarity arises when one amino acid is replaced by a similar residue, preserving the physicochemical properties. For example, a change from arginine to lysine maintains a +1 positive charge. This change is more likely to be acceptable because the two residues have similar properties and do not impair the function of the peptide. Therefore, the percentage of similarity of two sequences is the sum of the identity matches plus the similarity matches. The degree of similarity depends on the criteria used to compare the two amino acid residues.

[0163] For example, the RiLK1 peptide (RLKWVRIWRR, SEQ ID NO: 1) and the prior art HE10 peptide (VRLIVRIWRR, SEQ ID NO: 33) differ from each other at four positions out of a total of 10 positions. Thus, they have 60% identity. However, considering the four substitution pairs, R>V, L>R, K>L, W>I, it appears that the biochemical properties and the size of the residues in each pair are significantly different. Thus, as shown below, substitutions of the first four residues in the RiLK1 peptide significantly alter the physico-chemical and structural properties of the peptide compared to HE10.

[0164] RLK VRIWRR peptide-RiLK1 (SEQ ID NO: 1)

[0165] VRLI VRIWRR peptide HE10 (SEQ ID NO: 33)

[0166] Underlined residues correspond to positions that differ between the two peptides.

[0167] As clearly shown in Table 5, the hydrophobicity, hydrophilicity, amphipathicity, affinity, net charge and disordered conformational tendency of the claimed RiLK1 peptide differ significantly from those of HE10. These properties are known to strongly influence the properties of peptides and modulate their physicochemical characteristics, thereby having a corresponding impact on antimicrobial activity [Yang Wang, Jianbo Chen, Xin Zheng, Xiaoli Yang, Panpan M, Ying Cai, Bangzhi Zhang and Yuan Chena (2014). Design of novel analogues of short antimicrobial peptide anoplin with improved antimicrobial activity. J. Pept. Sci.; 20: 945–951. DOI 10.1002 / psc.2705; Hyung-SikWon, Min-Duk Seo, Seo-Jeong Jung, Sang-Jae Lee, Su-Jin Kang, Woo-Sung Son, Hyun-Jung Kim, Tae-Kyu Park, Sung-Jean Park, and Bong-Jin Lee, Structural Determinants for the Membrane Interaction of Novel Bioactive Undecapeptides Derived from Gaegurin 5. J. Med. Chem. 2006, 49, 4886-4895]. Hydrophobicity is known to affect mammalian cytotoxicity and antibacterial activity. Hydrophobic residues promote interactions with fatty acyl chains. Relatively low hydrophobicity prevents binding to zwitterionic membranes found in mammalian cells, resulting in low toxicity. However, hydrophobicity is required for permeabilization of bacterial membranes, but some studies have shown that further increases beyond the optimal hydrophobicity level can lead to loss of antibacterial activity and increased toxicity. Amphipathicity reflects the possibility of an amino acid sequence to form well-structured hydrophobic and hydrophilic domains on opposite faces. The Bowman index was originally designated as protein binding potential and was later renamed the Bowman index. This function calculates the sum of the solubility values ​​of all residues in the sequence and, for normalization, is divided by the number of residues. The Bowman index provides an overall estimate of the membrane binding potential of a peptide. The tendency of a protein or peptide to an (essentially) disordered conformation plays a key role in cellular regulation and signaling processes. Proteins and peptides display marginal structural stability under different biological conditions and repeatedly unfold and fold in vivo.In fact, a large number of studies have shown that the effects of the denatured state, such as residual structure, excluded volume and intrinsic conformational preferences, play a key role in molecular recognition, allosteric signaling, folding and stability [Peter Tompa, Eva Schad, Agnes Tantos and Lajos Kalmar (2015). Intrinsically disordered proteins: emerging interaction specialists. Current Opinion in Structural Biology, 35: 49–59. doi.org / 10.1016 / j.sbi.2015.08.009].

[0168] Table 5

[0169] RiLK HE10 Half-life (seconds) 855.71 835.91 Hydrophobicity -0.56 -0.36 Hydrophilicity -1.12 0.23 Amphiphilic 1.35 0.98 Affinity 0.31 0.02 Net charge 5.0 4.0 Bowman Index 4.67 3.45 Disordered conformation preference -0.61 -0.09

[0170] Table 5 thus clearly shows that the RiLK1 peptide used in the present invention and the HE10 peptide of the prior art show considerable differences in their chemical-physical properties. Therefore, a 60% identity percentage (which should in any case be considered lower) does not seem to be in any way to be considered as predictive of chemical-physical and thus functional similarities between the two peptides.

[0171] This is further confirmed by the data in Table 6, which shows the same predictions made by the same algorithm for 4 other AMP peptides of the present invention. These 4 peptides also exhibit hydrophobicity values, hydrophilicity values, amphipathicity values, affinity values, net charge values, Bowman index values, and disordered conformation tendency values ​​that are similar to each other and to RiLK1, but completely different from HE10.

[0172] Table 6

[0173] RiLK1 RiLK2 RiLK 7LKR RiLK23 HE10 Half-life (seconds) 855.71 855.71 920.11 855.71 920.11 835.91 Hydrophobicity -0.56 -0.56 -0.49 -0.56 -0.49 -0.36 Hydrophilicity -1.12 -1.12 -1.06 -1.12 -1.06 0.23 Amphiphilic 1.35 0.98 Affinity 0.31 0.31 0.31 0.31 0.31 0.02 Net charge 5.0 5.0 5.0 5.0 5.0 4.0 Bowman Index 4.66 4.66 5.6 4.66 3.73 3.45 Disordered conformation preference -0.61 -0.61 -0.62 -0.61 -0.59 -0.09

[0174] The inventors have also found that the presence of more than one tryptophan (W) residue, a feature common to all AMP peptides of the present invention, plays an important role in determining the antimicrobial properties, as it represents an advantageous and unique feature of the interfacial region between lipid bilayers. It is also known that the side chains of tryptophan residues participate in peptide folding in aqueous solution [David I. Chan, Elmar J. Prenner, Hans J. Vogel (2006). Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochimica et Biophysica Acta 1758; 1184–1202 doi: 10.1016 / j.bbamem.2006.04.006]. Considering the influence of primary and secondary structures on antibacterial activity, the ability to present an amphipathic structure is an important functional feature of AMP incorporation into bacterial membranes [Marlon H. Cardoso, Karen GNO Shiro, Samilla B. Rezende, Elizabete S. Candido, Octávio L. Franco. The Structure / Function Relationship in Antimicrobial Peptides: What Can we Obtain From Structural Data? Advances in Protein Chemistry and Structural Biology February 2018, DOI: 10.1016 / bs.apcsb.2018.01.008]. All AMP peptides of the present invention have at least a second tryptophan residue inserted in the central part of the sequence, the purpose of which is to enhance the amphipathicity of the helix.

[0175] NMR analysis of the RiFK1 peptide in a micellar environment (SDS) clearly demonstrated the presence of a well-defined structure in a helical arrangement that places the positively charged side chains and the hydrophobic side chains on opposite sides. In this arrangement, all the charged side chains are oriented in the same direction and readily interact with the negatively charged surface of the SDS micelle.

[0176] Furthermore, the two side chains of the tryptophan residue present in the WXXXW motif characterizing all AMP peptides used in the present invention are located at a suitable distance to stack with each other, thus contributing to stabilizing the helix.

[0177] On the other hand, the HE10 decapeptide described in WO2015038339 and all its analogs of 10 amino acids in length No The WXXXW motif characterizes the AMP peptides used in the present invention and, for the reasons given above, represents a functionally important feature for bactericidal activity.

[0178] Therefore, the AMP peptide used in the present invention is structurally and functionally dissimilar to the HE10 peptide of the prior art. Sequence Listing <110> Materias srl <120> Antimicrobial tubular catheter <130> E0131456-PC1840EC <160> 33 <170> BiSSAP 1.3.6 <210> 1 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 1 Arg Leu Lys Trp Val Arg Ile Trp Arg Arg 1 5 10 <210> 2 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 2 Lys Leu Arg Trp Val Arg Ile Trp Arg Arg 1 5 10 <210> 3 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 3 Arg Leu Arg Trp Val Arg Ile Trp Arg Arg 1 5 10 <210> 4 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 4 Lys Leu Lys Trp Val Arg Ile Trp Arg Arg 1 5 10 <210> 5 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 5 Arg Leu Lys Trp Val Lys Ile Trp Arg Arg 1 5 10 <210> 6 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 6 Lys Leu Arg Trp Val Lys Ile Trp Arg Arg 1 5 10 <210> 7 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 7 Arg Leu Arg Trp Val Lys Ile Trp Arg Arg 1 5 10 <210> 8 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 8 Lys Leu Lys Trp Val Lys Ile Trp Arg Arg 1 5 10 <210> 9 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 9 Arg Leu Lys Trp Val Arg Ile Trp Lys Arg 1 5 10 <210> 10 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 10 Lys Leu Arg Trp Val Arg Ile Trp Lys Arg 1 5 10 <210> 11 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 11 Arg Leu Arg Trp Val Arg Ile Trp Lys Arg 1 5 10 <210> 12 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 12 Lys Leu Lys Trp Val Arg Ile Trp Lys Arg 1 5 10 <210> 13 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 13 Arg Leu Lys Trp Val Lys Ile Trp Lys Arg 1 5 10 <210> 14 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 14 Lys Leu Arg Trp Val Lys Ile Trp Lys Arg 1 5 10 <210> 15 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 15 Arg Leu Arg Trp Val Lys Ile Trp Lys Arg 1 5 10 <210> 16 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 16 Lys Leu Lys Trp Val Lys Ile Trp Lys Arg 1 5 10 <210> 17 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 17 Arg Leu Lys Trp Val Arg Ile Trp Arg Lys 1 5 10 <210> 18 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 18 Lys Leu Arg Trp Val Arg Ile Trp Arg Lys 1 5 10 <210> 19 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 19 Arg Leu Arg Trp Val Arg Ile Trp Arg Lys 1 5 10 <210> 20 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 20 Lys Leu Lys Trp Val Arg Ile Trp Arg Lys 1 5 10 <210> twenty one <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> twenty one Arg Leu Lys Trp Val Lys Ile Trp Arg Lys 1 5 10 <210> twenty two <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> twenty two Lys Leu Arg Trp Val Lys Ile Trp Arg Lys 1 5 10 <210> twenty three <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> twenty three Arg Leu Arg Trp Val Lys Ile Trp Arg Lys 1 5 10 <210> twenty four <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> twenty four Lys Leu Lys Trp Val Lys Ile Trp Arg Lys 1 5 10 <210> 25 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 25 Arg Leu Lys Trp Val Arg Ile Trp Lys Lys 1 5 10 <210> 26 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 26 Lys Leu Arg Trp Val Arg Ile Trp Lys Lys 1 5 10 <210> 27 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 27 Arg Leu Arg Trp Val Arg Ile Trp Lys Lys 1 5 10 <210> 28 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 28 Lys Leu Lys Trp Val Arg Ile Trp Lys Lys 1 5 10 <210> 29 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 29 Arg Leu Lys Trp Val Lys Ile Trp Lys Lys 1 5 10 <210> 30 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 30 Lys Leu Arg Trp Val Lys Ile Trp Lys Lys 1 5 10 <210> 31 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 31 Arg Leu Arg Trp Val Lys Ile Trp Lys Lys 1 5 10 <210> 32 <211> 10 <212> PRT <213> Artificial sequence <220> <223> AMP <400> 32 Lys Leu Lys Trp Val Lys Ile Trp Lys Lys 1 5 10 <210> 33 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HE10 <400> 33 Val Arg Leu Ile Val Arg Ile Trp Arg Arg 1 5 10

Claims

1. A tubular conduit comprising an outer surface and an inner surface, characterized in that At least a portion of the outer surface and / or the inner surface is functionalized with at least one antimicrobial peptide or a salt or solvate thereof consisting of an amino acid sequence having the following general formula: X1LX2WVX3IWX4X5 wherein X1, X2, X3, X4 and X5 are independently selected from K and R and wherein each amino acid is independently in the D or L configuration.

2. The tubular conduit according to claim 1, wherein: The at least one antimicrobial peptide is covalently linked to reactive groups present on the outer surface and / or inner surface of the tubular conduit or is contained in a coating attached thereto.

3. A tubular conduit according to claim 1 or 2, wherein: At least one of X1, X3, X4 and X5 has the meaning of R and / or X2 has the meaning of K.

4. The tubular conduit according to claim 1 or 2, wherein: X4 and X5 have the meaning of R.

5. The tubular conduit according to claim 1 or 2, wherein: X3, X4 and X5 have the meaning of R.

6. The tubular conduit according to claim 1 or 2, wherein: X1, X3, X4 and X5 have the meaning of R.

7. The tubular conduit according to claim 1 or 2, wherein: The at least one antimicrobial peptide consists of an amino acid sequence selected from the group consisting of RLKWVRIWRR (SEQ ID NO: 1), KLRWVRIWRR (SEQ ID NO: 2), RLRWVRIWRR (SEQ ID NO: 3), KLKWVRIWRR (SEQ ID NO: 4), RLKWVKIWRR (SEQ ID NO: 5), KLRWVKIWRR (SEQ ID NO: 6), RLRWVKIWRR (SEQ ID NO: 7), KLKWVKIWRR (SEQ ID NO: 8), RLKWVRIWKR (SEQ ID NO: 9), KLRWVRIWKR (SEQ ID NO: 10), RLRWVRIWKR (SEQ ID NO: 11), KLKWVRIWKR (SEQ ID NO: 12), RLKWVKIWKR (SEQ ID NO: 13), KLRWVKIWKR (SEQ ID NO: 14). NO: 14), RLRWVKIWKR (SEQ ID NO: 15), KLKWVKIWKR (SEQ ID NO: 16), RLKWVRIWRK (SEQ ID NO: 17), KLRWVRIWRK (SEQ ID NO: 18), RLRWVRIWRK (SEQ ID NO: 19), KLKWVRIWRK (SEQ ID NO: 20), RLKWVKIWRK (SEQ ID NO: 21), KLRWVKIWRK (SEQ ID NO: 22), RLRWVKIWRK (SEQ ID NO: 23), KLKWVKIWRK (SEQ ID NO: 24), RLKWVRIWKK (SEQ ID NO: 25), KLRWVRIWKK (SEQ ID NO: 26), RLRWVRIWKK (SEQ ID NO: 27), KLKWVRIWKK (SEQ ID NO: 28), RLKWVKIWKK (SEQ ID NO: 29), KLRWVKIWKK (SEQ ID NO: 30), RLRWVKIWKK (SEQ ID NO: 31) and KLKWVKIWKK (SEQ ID NO: 32), wherein each amino acid is independently in the D or L configuration.

8. The tubular conduit according to claim 1 or 2, which is a drinking straw or a medical tube.

9. A tubular conduit according to claim 1 or 2, which is a drinking straw which is incorporated in and optionally removable from a container.

10. The tubular conduit according to claim 1 or 2, wherein: The at least one antimicrobial peptide is present on the at least a portion of the outer surface and / or the inner surface of the tubular conduit in an amount of 1 to 10 nmol per cm 2 The surface.

11. The tubular conduit according to claim 1 or 2, wherein: The at least one antimicrobial peptide is present on the at least a portion of the outer surface and / or the inner surface of the tubular conduit in an amount of 1.5 to 3 nmol per cm 2 The surface.

12. A tubular conduit according to claim 1 or 2, made of polymeric material, glass or metal.

13. The tubular catheter according to claim 12, which is made of a polymeric material selected from the group consisting of: styrene block copolymers, polyolefin blends, elastomeric blends, thermoplastic polyurethanes, thermoplastic copolyesters, thermoplastic polyamides, polyethylene terephthalate, polyethylene 1,4-cyclohexanedimethylene terephthalate, polyethylene 2,6 naphthalate, polyolefins, polyvinylidene fluoride, polyethylene 2,6 naphthalate, acrylonitrile butadiene styrene, polyvinyl chloride, polyether block amides, biodegradable polymers and mixtures thereof.

14. The tubular conduit according to claim 13, wherein: The biodegradable polymer is selected from the group consisting of polylactic acid (PLA), polybutylene adipate-co-terephthalate (PBAT), polycaprolactone (PCL), modified starch or polyglycolic acid (PGA), polybutylene succinate (PBS), poly-hydroxyalkanoate (PHA) and mixtures thereof.

15. The tubular conduit of claim 13, wherein: The polyolefin is selected from the group consisting of polypropylene and polyethylene.

16. The tubular conduit according to claim 15, wherein: The polyethylene is selected from: high-density polyethylene and low-density polyethylene.

17. The tubular catheter of claim 14, made of polylactic acid.

18. Use of the antimicrobial peptide according to any one of claims 1 to 17 for preventing contamination of a tubular catheter by Gram-negative bacteria, Gram-positive bacteria and / or fungi.

19. The use according to claim 18, wherein The fungus is a yeast.

20. The use according to claim 18, wherein The tubular conduit is a drinking straw or a medical tube.

21. The use according to claim 18, wherein The tubular conduit is a drinking straw that is incorporated into the container and optionally removable from the container.